The doctors who have spent years studying the case call it "a series of fortunate events." What began as a remarkable response to chimeric antigen receptor (CAR) T cell therapy is now providing evidence about the human genome ...
May 30, 2018
0
114
A team of researchers with members affiliated with several institutions in the U.S. has found that some statins could enhance the efficacy of a chemotherapy drug used to fight blood cancers in mouse models. In their paper ...
Cancer patients who have compromised immune systems due to their disease or therapy remain at high risk for COVID-19 infection. It is why this population was one of the first to receive the COVID-19 vaccine. However, while ...
Mar 10, 2022
0
33
A new treatment using leukemia patients' own infection-fighting cells appears to protect them from infections and cancer recurrence following treatment with fludarabine-based chemotherapy, according to new research from the ...
Dec 12, 2011
0
0
A Massachusetts General Hospital (MGH) research team has found how a variant in an important epigenetic enzyme—previously associated by population-based genetic studies with Crohn's disease and other immune disorders—interferes ...
Mar 3, 2017
0
83
Several new targeted therapies have shown promise against advanced cancers of the blood, lungs, ovaries, and thyroid, according to research released Saturday at a major US cancer conference.
May 31, 2014
0
0
Two North Shore-LIJ Cancer Institute doctors, world-renowned for their research in chronic lymphocytic leukemia (CLL), weigh in on a German study of a new drug therapy for CLL in the March 20 edition of the New England Journal ...
Mar 19, 2014
0
0
A new, targeted approach to treating chronic lymphocytic leukemia has produced durable remissions in a Phase I/II clinical trial for patients with relapsed or resistant disease, investigators report at the 53rd Annual Meeting ...
Dec 11, 2011
0
1
A three-drug combination that sent chronic lymphocytic leukemia (CLL) into deep remission in a broad group of patients in a clinical trial is highly effective in patients with high-risk forms of the disease, a new, phase ...
Dec 10, 2022
0
45
An interim analysis of a phase Ib/II clinical trial indicates that a novel experimental agent for chronic lymphocytic leukemia (CLL) is highly active and well tolerated in patients who have relapsed and are resistant to other ...
Dec 11, 2011
0
0
